Home-Made Covid Vaccine Appeared to Work, but Questions Remained
By Kristen V Brown,
Bloomberg
| 10. 10. 2020
Josiah Zayner’s plan was simple: replicate a Covid-19 vaccine that had worked in monkeys, test it on himself and then livestream the experiment online over a period of months. Now, that improbable bid is over.
Around the world, dozens of Covid-19 vaccines are in human clinical trials involving tens of thousands of people. While vaccines typically take years to develop, U.S. scientists are racing to produce one in months through Operation Warp Speed. But Zayner, a one-time NASA researcher who left the scientific establishment in favor of engaging in do-it-yourself experiments, bet that by working outside regulatory structures, he could test a vaccine even more quickly and certainly more cheaply by giving it to himself.
Instead, Zayner discovered, testing a vaccine is far more complicated than he had imagined.
Even though his experiment yielded a promising result, Zayner found too many unanswered questions to say that it worked. For one, it wasn’t clear whether antibodies he found in his own body in extremely tiny measures before the experiment began made a difference. Zayner has long-believed that biohackers such as himself have the potential to make science move faster...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...